AbCellera to present Phase 2 ABCL635 data for menopause hot flashes at IMS World Congress 2026

• Abcellera flagged upcoming Phase 2 data for ABCL635, a non-hormonal antibody for menopausal hot flashes, at the IMS World Congress on Menopause.
• Results will be presented Oct. 1, 2026 in Rio de Janeiro in an oral session focused on menopausal symptoms.
• Interim findings from a Phase 1/2 study are set to cover efficacy and safety in postmenopausal women with moderate-to-severe vasomotor symptoms.
• The readout positions ABCL635 as a potential long-acting alternative to existing non-hormonal options, a key commercial angle in women’s health.
• The Phase 2 program is a randomized, double-blind, placebo-controlled trial designed to support further clinical development decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260916319324) on September 16, 2026, and is solely responsible for the information contained therein.